If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
183
results.
Updated on
07/11/2025 [06:52:00]
Results 175 to 183 of 183
Absstract of: AU2024241934A1
Described herein are lipid nanoparticle (LNP) formulations for the delivery of active agents, including Archexin.
Absstract of: AU2024237452A1
To provide lipid particles that can be produced without relying on PEG-modified lipids, that are superior in medicinal effect, safety, or stability to lipid particles that rely on PEG-modified lipids, or that have different immunodynamics than lipid particles that rely on PEG-modified lipids. Provided is a lipid particle, wherein the lipid particle contains an ionized lipid, a phospholipid, and a sterol as lipids constituting the lipid particle and contains a modified polysaccharide that includes a hydrophobic group.
Absstract of: AU2024250986A1
The present disclosure provides compositions which enable the delivery of cargo, including therapeutic agents such as RNA, to organs or tissues in addition to the liver, lungs, and spleen, such as brain, heart, kidney, and muscle tissue. More specifically, the compositions comprise a plurality of lipid particles comprising an agent, cationic lipids and ionizable lipid.
Absstract of: WO2025219707A1
Drug-eluting device The present invention relates to: (i) a drug delivery device comprising a fibrous material, said fibrous material comprising: (a) a first fibre which comprises: - a first polymeric material comprising a carbon nanoparticle covalently bonded to a polymer; and/or - a first acidic polysaccharide; and/or - a first protein; and (b) a drug, and a method of manufacture thereof, as well as said drug delivery device for use in administering a drug.
Absstract of: WO2025219528A1
Provided is a lipid mix composition for forming lipid nanoparticles (LNP) in association with a DNA, for use in transfecting a cell of hematopoietic lineage, the lipid mix composition comprising an ionizable lipid, a phospholipid, a stabilizer, and cholesterol. The LNP, a method of modifying cells of hematopoietic lineage using the LNP, a cell of hematopoietic lineage modified by the method, and a method of treatment for immune deficiency, cancer, autoimmune disease or genetic insufficiency are also provided.
Absstract of: WO2025219491A1
Provided are compositions and methods for transfecting a cell of hematopoietic lineage, using a lipid nanoparticle (LNP) that includes a lipid mix composition including an ionizable lipid, the lipid mix composition encapsulating an HDR template DNA comprising a gene of interest for insertion into a desired chromosomal locus.
Absstract of: WO2025219613A1
The present invention relates to particles comprising a polymer and DNA, wherein the DNA comprises at least one binding site capable of binding to RNA, in particular miRNA. Further, the invention is directed to a pharmaceutical composition comprising the particles and a pharmaceutically acceptable carrier. Moreover, the particles may be used in the treatment disease associated with RNA-overexpression.
Nº publicación: WO2025221757A1 23/10/2025
Applicant:
BOARD OF REGENTS THE UNIV OF TEXAS SYSTEM [US]
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
Absstract of: WO2025221757A1
The present invention relates to a carbohydrate-polymer conjugate comprising a repeat unit, a divalent linker, and a carbohydrate and compositions thereof, wherein the repeat unit comprises, in part, a linker and a carbohydrate, and a method comprising the step of administering a composition comprising the carbohydrate-polymer conjugate, wherein the composition can cross the blood-brain barrier.
BOPI
Electronic site
